Try
BRISTOL MYERS SQUIBB CO
BMYUnited States
71 filed reports · 780 financial concepts · 41 earnings calls · 1 media appearances
Filed reports
71 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 25 operating metrics, 304 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 8,841 | Jun 2016 to Jun 2026 |
| Current · 8-KSEC EDGAR | 30 | 238 | Mar 2019 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 8,361 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 30, 2026 | 591 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 30, 2026 | 8 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 30, 2026 | 6 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 30, 2026 | 401 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 11, 2026 | 1,459 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 5, 2026 | 8 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Oct 30, 2025 | 8 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Oct 30, 2025 | 382 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 31, 2025 | 247 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 31, 2025 | 8 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | Apr 24, 2025 | 8 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | Apr 24, 2025 | 263 | Open |
Financial data
780 concepts · 17,440 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial755 concepts · 15,700 facts · Dec 2014 to Jul 2026
- Research and development131 · Dec 2015 to Jun 2026
- Cash and cash equivalents at carrying value59 · Dec 2014 to Jun 2026
- Restructuring reserve59 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Profit loss58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Assets57 · Mar 2015 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Comprehensive income net of tax including portion attributable to noncontrolling interest57 · Dec 2014 to Jun 2026
- Costs and expenses57 · Dec 2014 to Jun 2026
- Gain loss related to litigation settlement57 · Dec 2014 to Jun 2026
- Income tax expense benefit57 · Dec 2014 to Jun 2026
- Investment income interest57 · Dec 2014 to Jun 2026
- Other57 · Dec 2014 to Jun 2026
- Other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment net of tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss net of tax57 · Dec 2014 to Jun 2026
- Other comprehensive income loss pension and other postretirement benefit plans adjustment net of tax57 · Dec 2014 to Jun 2026
- Other nonoperating income expense57 · Dec 2014 to Jun 2026
- Research and development expense57 · Dec 2014 to Jun 2026
- Restructuring charges57 · Dec 2014 to Jun 2026
- Selling general and administrative expense57 · Dec 2014 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest57 · Mar 2015 to Jun 2026
- Amortization of intangible assets56 · Dec 2014 to Jun 2026
Product2 concepts · 1,223 facts · Dec 2014 to Jun 2026
- Revenue1,222 · Dec 2014 to Jun 2026
- Mavacamten1 · Dec 2022
Geography13 concepts · 278 facts · Dec 2014 to Jun 2026
- Revenue210 · Dec 2014 to Jun 2026
- Property, Plant & Equipment, Net29 · Dec 2015 to Dec 2025
- Charge-backs and cash discounts17 · Mar 2023 to Jun 2026
- Japan4 · Dec 2014 to Dec 2017
- Switzerland4 · Dec 2025
- Effective income tax rate reconciliation foreign income tax rate differential3 · Dec 2025
- Income tax reconciliation foreign income tax rate differential3 · Dec 2025
- Effective income tax rate reconciliation other adjustments2 · Dec 2025
- Income tax reconciliation other adjustments2 · Dec 2025
- Effective income tax rate reconciliation cross border other amount1 · Dec 2025
- Effective income tax rate reconciliation cross border other percent1 · Dec 2025
- Effective income tax rate reconciliation tax credits1 · Dec 2025
- Income tax reconciliation tax credits1 · Dec 2025
Guidance9 concepts · 238 facts · Apr 2019 to Jul 2026
- EPS (Diluted) Guidance62 · Apr 2019 to Jul 2026
- Effective Tax Rate Guidance56 · Apr 2019 to Jul 2026
- Gross Margin Guidance56 · Apr 2019 to Jul 2026
- Revenue Guidance28 · Feb 2020 to Jul 2026
- EPS (Diluted) Guidance (Adjusted (non-GAAP))10 · May 2020 to Nov 2020
- Revenue Growth Guidance8 · Feb 2021 to Oct 2024
- Effective Tax Rate Guidance (Adjusted (non-GAAP))6 · May 2020 to Nov 2020
- Gross Margin Guidance (Adjusted (non-GAAP))6 · May 2020 to Nov 2020
- Revenue Guidance (Adjusted (non-GAAP))6 · May 2020 to Nov 2020
Segment1 concepts · 1 facts · Mar 2018
- Japan1 · Mar 2018
Segments
1,502 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis45 members · 1,010 facts
- Eliquis44 · Dec 2016 to Jun 2026
- Opdivo44 · Dec 2016 to Jun 2026
- Orencia44 · Dec 2016 to Jun 2026
- Sprycel44 · Dec 2016 to Jun 2026
- Yervoy44 · Dec 2016 to Jun 2026
- Abraxane39 · Dec 2017 to Jun 2026
- Pomalyst Imnovid39 · Dec 2017 to Jun 2026
- Revlimid39 · Dec 2017 to Jun 2026
- Reblozyl38 · Dec 2018 to Jun 2026
- Zeposia37 · Dec 2018 to Jun 2026
- Breyanzi32 · Dec 2019 to Jun 2026
- Abecma30 · Dec 2019 to Dec 2025
- Opdualag28 · Dec 2020 to Jun 2026
- Camzyos27 · Dec 2020 to Jun 2026
- Empliciti27 · Dec 2016 to Dec 2022
- Inrebic27 · Dec 2017 to Dec 2023
- Sotyktu26 · Dec 2020 to Jun 2026
- Alliance Revenues24 · Dec 2020 to Jun 2026
- Mature Products And All Other24 · Dec 2016 to Dec 2023
- Net Product Sales24 · Dec 2020 to Jun 2026
- Onureg24 · Dec 2018 to Dec 2023
- Sales Revenue Gross24 · Dec 2020 to Jun 2026
- Alliance And Other Revenues21 · Dec 2020 to Jun 2026
- Baraclude20 · Dec 2016 to Sep 2021
- Other Revenues20 · Dec 2020 to Jun 2026
- Growth Brands18 · Dec 2022 to Jun 2026
- Krazati18 · Dec 2022 to Jun 2026
- Legacy Brands18 · Dec 2022 to Jun 2026
- Other Growth Brands18 · Dec 2022 to Jun 2026
- Other Legacy Brands18 · Dec 2022 to Jun 2026
- Vidaza15 · Dec 2017 to Sep 2021
- Cobenfy14 · Dec 2022 to Jun 2026
- In Line Products13 · Sep 2021 to Dec 2023
- In Line Products And New Product Portfolio13 · Sep 2021 to Dec 2023
- LOE Products13 · Sep 2021 to Dec 2023
- New Product Portfolio13 · Sep 2021 to Dec 2023
- Opdivo Ovantig13 · Dec 2023 to Jun 2026
- Augtyro12 · Dec 2021 to Dec 2024
- Mature And Other Brands9 · Mar 2021 to Sep 2023
- Other Revenue Hedging Activities4 · Mar 2025 to Jun 2026
- Hepatitis C Portfolio3 · Dec 2016 to Dec 2018
- Reyataz3 · Dec 2016 to Dec 2018
- Sustiva Franchise3 · Dec 2016 to Dec 2018
- Alliance revenues1 · Mar 2024
- Mavacamten1 · Dec 2022
Product or serviceus-gaap:ProductOrServiceAxis15 members · 213 facts
- Baraclude18 · Dec 2014 to Sep 2018
- Eliquis18 · Dec 2014 to Sep 2018
- Hepatitis C Portfolio18 · Dec 2014 to Sep 2018
- Opdivo18 · Dec 2014 to Sep 2018
- Orencia18 · Dec 2014 to Sep 2018
- Reyataz18 · Dec 2014 to Sep 2018
- Sprycel18 · Dec 2014 to Sep 2018
- Sustiva Franchise18 · Dec 2014 to Sep 2018
- Yervoy18 · Dec 2014 to Sep 2018
- Mature Products And All Other15 · Dec 2014 to Dec 2017
- Empliciti14 · Dec 2015 to Sep 2018
- Abilify9 · Dec 2014 to Dec 2016
- Other Region6 · Mar 2017 to Sep 2018
- Erbitux5 · Dec 2014 to Dec 2015
- Mature products and all other2 · Dec 2019 to Dec 2021
Statement geographicalsrt:StatementGeographicalAxis11 members · 206 facts
- US61 · Dec 2016 to Jun 2026
- Other Region44 · Dec 2016 to Jun 2026
- European Union23 · Dec 2016 to Dec 2022
- Rest Of World23 · Dec 2016 to Mar 2022
- International18 · Jun 2021 to Mar 2025
- Non Us13 · Dec 2022 to Jun 2026
- CH10 · Dec 2025
- IE6 · Dec 2025
- International4 · Dec 2021 to Dec 2024
- Foreign Tax Jurisdiction Other2 · Dec 2025
- Non us2 · Dec 2024 to Dec 2025
Statement geographicalus-gaap:StatementGeographicalAxis9 members · 72 facts
- Us12 · Dec 2015 to Dec 2025
- European Union11 · Dec 2014 to Sep 2018
- Rest Of World11 · Dec 2014 to Sep 2018
- US11 · Dec 2014 to Sep 2018
- Other Region10 · Dec 2014 to Sep 2018
- Europe7 · Dec 2015 to Dec 2021
- Rest of world5 · Dec 2015 to Dec 2021
- JP4 · Dec 2014 to Dec 2017
- European union1 · Dec 2020
Statement business segments1 member · 1 facts
- Sales Revenue Net1 · Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary146 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary242 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes5 claims from 1 reports · Dec 2025
- Risk factors46 risks from 2 annual reports · 2024 to 2025
Earnings calls
41 calls · Jul 2016 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 30, 2026
- FY2026 Q1Apr 30, 2026
- FY2025 Q4Feb 5, 2026
- FY2025 Q3Oct 30, 2025
- FY2025 Q2Jul 31, 2025
- FY2025 Q1Apr 24, 2025
- FY2024 Q4Feb 6, 2025
- FY2024 Q3Oct 31, 2024
- FY2024 Q2Jul 26, 2024
- FY2024 Q1Apr 25, 2024
- FY2023 Q4Feb 2, 2024
- FY2023 Q3Oct 26, 2023
- FY2023 Q2Jul 27, 2023
- FY2023 Q1Apr 27, 2023
- FY2022 Q4Feb 2, 2023
- FY2022 Q3Oct 26, 2022
Executive media
1 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews1 · Jan 2020
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.